tetano
Editor, Senior Moderator
Vet Microbiol
. 2022 Jun 9;271:109491.
doi: 10.1016/j.vetmic.2022.109491. Online ahead of print.
An influenza virus vector candidate vaccine stably expressing SARS-CoV-2 receptor-binding domain produces high and long-lasting neutralizing antibodies in mice
Yongzhen Zhao[SUP] 1 [/SUP], Lingcai Zhao[SUP] 2 [/SUP], Yingfei Li[SUP] 3 [/SUP], Qingzheng Liu[SUP] 4 [/SUP], Lulu Deng[SUP] 5 [/SUP], Yuanlu Lu[SUP] 6 [/SUP], Xiaoting Zhang[SUP] 7 [/SUP], Shengmin Li[SUP] 8 [/SUP], Jinying Ge[SUP] 9 [/SUP], Zhigao Bu[SUP] 10 [/SUP], Jihui Ping[SUP] 11 [/SUP]
Affiliations
Abstract
Viral infectious pathogens, such as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza virus, can cause extremely high infection rates and mortality in humans. Therefore, it is urgent to develop an effective vaccine against coronavirus and influenza virus infection. Herein, we used the influenza virus as a vector to express the SARS-CoV-2 spike receptor-binding domain (RBD) and hemagglutinin-esterase-fusion (HEF) protein of the influenza C virus. We then evaluated the feasibility and effectiveness of this design strategy through experiments in vitro and in vivo. The results showed that the chimeric viruses could stably express the HEF protein and the SARS-CoV-2 spike RBD at a high level. BALB/c mice, infected with the chimeric virus, exhibited mild clinical symptoms, yet produced high specific antibody levels against RBD and HEF, including neutralizing antibodies. Importantly, high neutralizing antibodies could be retained in the sera of mice for at least 20 weeks. Altogether, our data provided a new strategy for developing safe and effective COVID-19 and influenza virus vaccines.
Keywords: Influenza C virus; Influenza virus vector; Live attenuated vaccine; Receptor-binding domain; SARS-CoV-2.
. 2022 Jun 9;271:109491.
doi: 10.1016/j.vetmic.2022.109491. Online ahead of print.
An influenza virus vector candidate vaccine stably expressing SARS-CoV-2 receptor-binding domain produces high and long-lasting neutralizing antibodies in mice
Yongzhen Zhao[SUP] 1 [/SUP], Lingcai Zhao[SUP] 2 [/SUP], Yingfei Li[SUP] 3 [/SUP], Qingzheng Liu[SUP] 4 [/SUP], Lulu Deng[SUP] 5 [/SUP], Yuanlu Lu[SUP] 6 [/SUP], Xiaoting Zhang[SUP] 7 [/SUP], Shengmin Li[SUP] 8 [/SUP], Jinying Ge[SUP] 9 [/SUP], Zhigao Bu[SUP] 10 [/SUP], Jihui Ping[SUP] 11 [/SUP]
Affiliations
- PMID: 35714529
- DOI: 10.1016/j.vetmic.2022.109491
Abstract
Viral infectious pathogens, such as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza virus, can cause extremely high infection rates and mortality in humans. Therefore, it is urgent to develop an effective vaccine against coronavirus and influenza virus infection. Herein, we used the influenza virus as a vector to express the SARS-CoV-2 spike receptor-binding domain (RBD) and hemagglutinin-esterase-fusion (HEF) protein of the influenza C virus. We then evaluated the feasibility and effectiveness of this design strategy through experiments in vitro and in vivo. The results showed that the chimeric viruses could stably express the HEF protein and the SARS-CoV-2 spike RBD at a high level. BALB/c mice, infected with the chimeric virus, exhibited mild clinical symptoms, yet produced high specific antibody levels against RBD and HEF, including neutralizing antibodies. Importantly, high neutralizing antibodies could be retained in the sera of mice for at least 20 weeks. Altogether, our data provided a new strategy for developing safe and effective COVID-19 and influenza virus vaccines.
Keywords: Influenza C virus; Influenza virus vector; Live attenuated vaccine; Receptor-binding domain; SARS-CoV-2.